摘要
细胞周期的调控机制在肿瘤的发生、发展中发挥着重要作用。多项研究表明,在雌激素受体阳性、人类表皮生长因子受体阴性的乳腺癌患者中,细胞周期蛋白依赖性激酶4/6(cyclin-dependent kinase 4/6,CDK4/6)抑制剂具有较好的疗效,然而其在三阴性乳腺癌患者中的疗效仍需进一步探讨。Cyclin D-CDK4/6-INK4-Rb-E2F信号通路因具有调控细胞周期检查点的作用,被认为是乳腺癌潜在的治疗靶点。寻找三阴性乳腺癌与CDK4/6抑制剂关联的生物标志物,探究合理的药物配伍,筛选能从中获益的靶向人群,对临床工作具有重要意义。对CDK4/6抑制剂在三阴性乳腺癌的研究进展进行综述,探讨其应用前景及优化手段。
The regulatory mechanism of cell cycle plays an important role in the occurrence and development of tumors.In recent years,a number of studies have shown that cyclin-dependent kinase 4/6(CDK4/6)inhibitors have good efficacy in patients with estrogen receptor-positive,human epidermal growth factor receptor-negative breast cancer,but their efficacy in patients with triple-negative breast cancer is still controversial.Cyclin D-CDK4/6-INK4-Rb-E2 F signaling pathway is considered as a potential therapeutic target for breast cancer due to its role in regulating cell cycle check points.It is of great significance to explore the molecular markers related to CDK4/6 inhibitors for triple-negative breast cancer,guide rational drug combination,and screen the population of triple-negative breast cancer patient who can benefit from this drug.In this article,we reviewed the research progress of CDK4/6 inhibitors in triple-negative breast cancer,and discussed their application prospects and optimization methods.
作者
朱秀之
陈力
纪磊
高雨
王中华
ZHU Xiuzhi;CHEN Li;JI Lei;GAO Yu;WANG Zhonghua(Department of Breast Surgery,Key Laboratory of Breast Cancer in Shanghai,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2019年第11期899-905,共7页
China Oncology
基金
北京乳腺病防治学会乳腺癌预防与诊治科研基金（2016）
上海市抗癌协会青年医生“雏鹰”项目（2018)(SACA-CY1B02）
